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Research gaps in neonatal HIV-related care
The South African (SA) prevention of mother to child transmission (PMTCT) programme 
has made excellent progress in reducing vertical HIV transmission.1,2 In addition,1 paediatric 
antiretroviral therapy (ART) programmes have demonstrated good outcomes with increasing 
treatment initiation in younger children and infants, in response to South African and World 
Health Organization (WHO) guidelines expanding recommendations for immediate ART from 
infants to all children < 5 years old.2,3,4,5,6,7,8,9,10 However, both in SA and across sub-Saharan 
African, lack of boosted peri-partum prophylaxis for high-risk vertical transmission, loss to 
follow-up (LTFU) for early infant diagnostic (EID) HIV-polymerase chain reaction (PCR) 
testing and receipt of results, and failure to initiate HIV-infected infants on ART before disease 
progression are key remaining gaps in neonatal HIV-related care.11,12,13 The expert reviews on 
recognising and managing vertical transmission risk in the peri-partum period,14 HIV diagnostic 
testing of newborns15 and provision of neonatal ART16 provide valuable recommendations for 
addressing these coverage gaps. They also highlight a number of areas where evidence is lacking 
to inform guidelines and programme development for optimal neonatal HIV-related care.
What is the best way to manage newborns at increased risk of intrapartum 
HIV transmission?
For many years, guidelines from developed countries17,18,19 included identification of neonates 
at high risk of vertical transmission,20,21 recommending multi-antiretroviral (multi-ARV) post-
exposure prophylaxis (PEP) for these neonates. While two studies provide direct evidence that 
multi-ARV PEP is more effective than a single drug,22,23 data are lacking on the best choice, 
number and duration of drugs.
Research is needed to inform guidelines that balance the prophylactic benefit of multi-ARV 
PEP with risks of toxicity and resistance that may increase with duration, as well as the 
programmatic challenges associated with effectively implementing more complex regimens 
for longer periods. Furthermore, longer-duration multi-ARV PEP may suppress HIV viral 
load,23,24,25 making HIV diagnosis more challenging, with implications for EID algorithms. In 
wealthy countries with low maternal HIV prevalence, reduced sensitivity of HIV-PCR is of less 
concern as guidelines recommend EID testing at numerous time points in exposed infants. In 
contrast, in South Africa, routine testing in otherwise well infants will probably be restricted 
to two HIV-PCR tests per infant at most, hence the impact of reduced sensitivity of HIV-PCR 
testing is critical.
Research needs include determining the effectiveness of routine programmes in accurately 
identifying high-risk infants in need of multi-ARV PEP, as well as retention, adherence and 
transmission in routine care. For example, monitoring and evaluation of the implementation of 
the National and Western Cape provincial guidelines for multi-ARV PEP could provide valuable 
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The South African prevention of mother to child transmission programme has made excellent 
progress in reducing vertical HIV transmission, and paediatric antiretroviral therapy 
programmes have demonstrated good outcomes with increasing treatment initiation in 
younger children and infants. However, both in South Africa and across sub-Saharan African, 
lack of boosted peri-partum prophylaxis for high-risk vertical transmission, loss to follow-
up, and failure to initiate HIV-infected infants on antiretroviral therapy (ART) before disease 
progression are key remaining gaps in neonatal HIV-related care. In this issue of the Southern 
African Journal of HIV Medicine, experts provide valuable recommendations for addressing 
these gaps. The present article highlights a number of areas where evidence is lacking to 
inform guidelines and programme development for optimal neonatal HIV-related care.
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What are the optimal algorithms for early infant 
diagnostic?
South African 2014 PMTCT guidelines provide for HIV-
PCR testing at birth of HIV-exposed infants at high risk of 
vertical HIV transmission, including low-birthweight and 
premature infants as well as those born to mothers on ART 
for < 4 weeks or with HIV-RNA > 1000 copies/mL.26 In 
addition, a WHO technical expert panel in 2013 reviewed 
the optimal timing of EID testing, and consideration was 
given to recommending either universal or risk-based birth 
testing.27 Given the shift towards a greater proportion of in 
utero infections with improved coverage of more effective 
PMTCT regimens such as Option B/B+, and the proven 
efficacy of HIV-PCR at birth to identify 75% of infections 
detectable by 6 weeks of age, birth EID could be pivotal 
in mitigating against the high LTFU for EID testing and 
delays in starting infected infants on ART.23,28 However, 
there are a number of questions regarding optimal EID 
guidelines.
What is the best time for a follow-up HIV-polymerase 
chain reaction test?
Birth testing necessitates a follow-up test, as 25% of early 
HIV infections are undetectable at birth.23,28 Evidence is 
needed to inform the optimal timing of follow-up testing, 
which depends on test performance, morbidity and 
mortality without ART (and the effect of ART in reducing 
this), retention strategies and operational considerations 
of aligning follow-up with routine child health visits.27,29 
Whilst mathematical modelling suggests that, with two 
HIV-PCR tests per infant, the greatest number of infections 
can be identified at birth and 10 weeks of age, there is a 
need for more evidence to inform the model assumptions, 
such as the probable loss of HIV-PCR sensitivity owing to 
nevirapine PEP.30 Of note, no studies to date have examined 
HIV-PCR test performance at birth and thereafter, now that 
triple ART is mandated for all women during pregnancy 
and breastfeeding together with extended infant NVP 
prophylaxis. These factors may all reduce test sensitivity 
at birth31 and at 6 weeks of age.25 For this reason, the 2014 
South African PMTCT guidelines defer PCR testing to 16 
weeks of age in infants who need 12 weeks of NVP PEP.26 
However, more data are needed on the duration and extent 
of reduced sensitivity post-PEP.24 Delaying testing will 
improve sensitivity; however, attrition is likely to increase 
at longer post-partum durations.32 The extent to which such 
attrition would be exacerbated by false reassurance of a 
negative result at birth is unknown.
In addition, the model assumes that ART very early in life 
is associated with improved survival. However, there are 
little data on the magnitude of the mortality benefit when 
ART is initiated very early, for example in the first days 
or weeks of life, especially in premature low-birthweight 
infants, compared with the benefit seen in the Children 
with HIV Early antiRetroviral (CHER) trial where the 
median age of ART initiation in the early group was 7.4 
weeks.33
Is it efficient to test all infants routinely at birth, or should 
this be restricted to those at high risk of transmission?
Whilst the mathematical modelling study demonstrates a 
nearly 50% increase in the number of life years saved when 
adding a routine birth test to a single test at 10 weeks of age, 
more tests increase costs and reduce efficiency (measured in 
terms of new diagnoses per PCR) by approximately 35%.30 
The efficiency of restricting birth testing to those at high risk 
of transmission is unknown and may be programmatically 
more difficult to implement effectively. In particular, more 
data would be needed to identify easily implementable 
high-risk criteria that are predictive of a high likelihood of a 
positive birth test.
Although the specificity, and therefore positive predictive 
value (PPV) of currently used EID tests is very high, the 
proportion of false-positive tests increases with reduced 
transmission rates. Follow-up confirmatory testing with 
HIV-PCR or viral load may be difficult to interpret in infants 
on prophylactic therapy,25 with careful counselling needed. 
Research is needed on how best to manage patients with 
false-positive or indeterminate test results, which may be 
resource-intensive and difficult outside specialist facilities.
How feasible is implementation of birth testing in routine 
care settings?
EID testing at 6 weeks and follow-up for results at the 10-week 
immunisation visit is currently performed at immunisation 
clinics. For a birth PCR, delivery facilities would be 
responsible for birth testing. The very high proportion of 
facility-based deliveries in SA favours birth testing, and 
routine postnatal follow-up within a few days of birth at 
many delivery facilities could facilitate receipt of results. 
However, the extent to which the additional workload can be 
absorbed by delivery facilities is unclear. This consideration 
is particularly important for high-burden facilities where 
women may be discharged within hours of delivery so 
that counselling and birth tests may need to be performed 
after hours or on weekends. There are encouraging early 
data from a pilot study comparing birth testing of high-risk 
infants in primary (Khayelitsha, Cape Town) and tertiary 
(Tygerberg Hospital, Cape Town) care delivery facilities, 
supporting the feasibility of implementing birth testing 
at primary care level.34 There was no difference in median 
time-to-test results between the facilities despite no on-site 
laboratory at the primary care facility.34 However, additional 
research staff supported the study and testing was limited to 
high-risk infants (about 25% of all exposed infants), therefore 
the results may not be generalisable to all infants in routine 
care settings.
Research is also needed on how best to counsel mothers of 
infants whose birth test is negative about the need to return 
for an additional test. Systems to ensure follow-up for a 
subsequent test require development. This approach may 
be challenging, especially in the absence of unique patient 
identifiers across the health service, as subsequent tests in 
infants born at a single delivery facility would probably 
occur in many different immunisation clinics.
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How do we ensure that patients return for results and 
initiate antiretroviral therapy if indicated?
Irrespective of the timing of testing, there is a need to develop 
and evaluate systems for ensuring that positive infant results 
are received and ART is successfully initiated. Interestingly, 
in the modelling study, changing the timing of a second HIV-
PCR test between 6 and 14 weeks of age had only a small effect 
on the proportion of perinatal infections diagnosed,30 whereas 
the greatest reduction in missed diagnoses (11%) was seen if 
100% of caregivers received test results, compared with the 
assumption of 66% based on previous studies.35,36 Data from 
the Western Cape reassuringly suggest that the proportion of 
infected infants linked to HIV care has increased from 54% 
to 71% between 2005 and 2010.37 It is likely that there have 
been further improvements, with rapid alerts of positive tests 
from laboratories to sub-district PMTCT co-ordinators and 
immunisation clinics, with follow-up tracing of infants. (Van 
Niekerk, personal comm.). In contrast, in rural KwaZulu-
Natal in 2012, 45% of infants with positive HIV-PCR 
diagnoses never started ART and a number of challenges 
in tracing infected infants were identified, highlighting the 
need for better linkage systems in a range of settings.38
Point-of-care (POC) tests could maximise the proportion 
of infants receiving results, with a number of platforms 
currently under investigation.29 A recent Mozambique 
study demonstrated 98.5% sensitivity and 99.9% specificity, 
comparing a POC nucleic acid test implemented in primary 
care clinics with laboratory tests.39 Similar encouraging 
results were reported for a POC nucleic acid test in Cape 
Town, South Africa, with overall sensitivity of 97% and 
specificity of 100% for correctly identifying HIV-infected 
infants.40 Sensitivity was slightly lower (93%) and the test 
error rate higher (10%) among 90 infants tested at < 7 days 
old.40 Further studies of birth POC tests are ongoing. In 
addition, the throughput time for a single POC test may limit 
its use in busier facilities, especially if testing is done on all 
infants, and not only those at high risk.
Despite the research gaps and challenges described, 
implementation of routine birth testing in all infants with 
nearly 100% coverage could itself provide much-needed 
evidence of the real effectiveness of the PMTCT programme 
and monitor progress towards virtual elimination of vertical 
transmission of HIV. Mother to child transmission is probably 
currently under-estimated both by routine statistics and 
dedicated studies, as a high proportion of HIV-infected infants 
may be LTFU or deceased by 6 weeks of age.2,28 Similarly, 
owing to current under-diagnosis of all neonatal infections, the 
true neonatal mortality in HIV-infected infants is unknown.15
What is the best management for HIV-infected 
neonates?
How soon after birth should antiretroviral therapy be 
started?
There is a spectrum of arguments favouring early infant 
ART ranging from the more conventional aims of reducing 
morbidity and mortality through effective therapy to the 
potential for modifying persistent HIV to facilitate later 
treatment-sparing or even eradication strategies.41,42,43,44,45 
Evidence for the traditional goal of reducing morbidity and 
mortality includes the high early mortality and rapid disease 
progression in HIV-infected infants,46,47,48 the lack of prognostic 
markers for mortality in infants49 and the substantial 
reductions in morbidity, mortality, neurodevelopmental 
delay and other HIV-related complications demonstrated 
in the CHER randomised controlled trial.33,50,51 In addition, 
cohort studies report better growth, neurocognitive 
outcomes, immunological response and virological control 
in infants starting therapy at earlier ages than amongst older 
infants and children.45,52,53,54,55,56,57,58,59
Whilst early virological control in infancy is important for 
the conventional treatment goals of optimal long-term 
outcomes on ART, it may also moderate chronic HIV 
infection by reducing the latent HIV reservoir, paving the 
way for treatment-sparing strategies.41,45,53,60 The case of 
the ‘Mississippi child’, who received triple therapy within 
hours of birth with early virological control and subsequent 
prolonged virological remission off ART,61 has sparked 
interest in treatment-sparing or cure approaches. The final 
results of the CHER trial found that early therapy followed by 
interruption after either 40 or 96 weeks on ART had superior 
clinical and immunological outcomes and less overall time 
on ART than deferred continuous therapy.44 However, it is 
not known whether longer duration or uninterrupted early 
therapy would have even better outcomes. In addition, 
detailed studies on the virological and immunological 
consequences of interruption, and predictors of the need to 
restart therapy in the interrupted groups, are still under way. 
Luzuriaga et al.53 recently showed that early treatment at < 
2.6 months of age with sustained virological control through 
to adolescence is associated with limited circulating pro-viral 
and replication competent virus with continuous decay of 
viral reservoirs, not seen in children starting ART at older 
ages. Nevertheless, whilst early virological control in infants 
may allow for later treatment interruptions or eradication 
strategies, it does not guarantee prolonged absence of 
viral rebound, which has occurred within days to weeks of 
stopping treatment.62,63
It is easy to merge the spectrum of arguments in favour of 
early infant ART into the general dictum ‘the sooner, the 
better’, especially with a shift towards birth EID testing. 
Indeed, the rapid disease progression and mortality in HIV-
infected infants by 2–3 months of age and high mortality 
even in the early treatment arm of the CHER trial suggests 
that ART initiation before a median of 7.4 weeks of age 
should be beneficial.33,46,64 However, we really do not know 
how soon is soon enough. There is no clear evidence on 
the optimal timing of ART between birth and 7.4 weeks for 
either reducing morbidity and mortality on ART, or later 
treatment-sparing approaches. Importantly, this evidence is 
also needed for pre-term and low-birthweight infants who 
comprise a substantial proportion of infants at risk of vertical 
transmission.21,65,66 Of note, low-birthweight infants (< 2kg) 
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were excluded from the CHER study.33 In addition, as studies 
demonstrating benefits of early infant ART to date have not 
distinguished between in utero and intrapartum infection, 
the optimal timing of ART initiation in these groups may 
differ.47,67
Which regimen should be used in the neonatal period?
The optimal timing of neonatal ART initiation must 
balance the benefits and risks of early therapy, and hence 
the lack of appropriate formulations or pharmacokinetic, 
dosing, safety and effectiveness data for drugs in neonates, 
especially premature neonates, as outlined in the companion 
article by Nuttall,16 are research gaps. In particular, the use 
of a nevirapine-based regimen in neonates < 2 weeks of 
age is a concern with high prevalence of Non-nucleoside 
reverse-transcriptase inhibitors (NNRTI) resistance, even 
in the absence of reported PMTCT exposure.68 Prevalence 
of resistance may be even higher than previously reported 
if more sensitive testing methods are used.69 There is 
mixed evidence on the benefit of more aggressive regimens 
that hasten virological control, for example four-drug 
regimens.54,70,71 Studies are warranted on the safety and 
effectiveness of different regimens, including triple-class 
four-drug regimens and integrase inhibitors. The role of 
these regimens may be particularly important if the goal of 
therapy is to allow for later treatment-sparing strategies.41 
In addition, as adult ART programmes mature, choice of 
regimen in infants born to mothers failing first-line ART is an 
emerging research need.
Evidence for which drugs to initiate should consider 
the likely characteristics and comorbidities in infants 
infected despite a comprehensive high-coverage PMTCT 
programme. In a case series of 20 infants initiating ART 
within the first 6 weeks of life at Rahima Moosa Mother 
and Child Hospital in Johannesburg, 70% had congenital 
infections and other illnesses requiring treatment.72 
Prematurity (70%), low birthweight (50%), and pre-
treatment thrombocytopaenia (30%), anaemia (40%) and 
renal dysfunction (10%) were not uncommon.72 Illnesses 
requiring treatment included congenital pneumonia, 
congenital syphilis, CMV and TB.72 Similar results have 
been reported from a case series of infants diagnosed 
at birth at Mowbray Maternity Hospital, Cape Town.73 
Drug interactions may occur and drugs may require 
administration via nasogastric or orogastric tubes in sick 
pre-term infants, affecting dose delivery.65
Given the lack of data on many drugs in the neonatal period 
and probable comorbidities in infected infants, appropriate 
safety and dose monitoring requires determination. For 
example, published studies of treated premature neonates 
have closely monitored drug levels to determine dosing, and 
the extent to which this is required routinely is unclear.65 
Similarly, the optimal intensity of safety monitoring is 
unknown both for sick neonates in hospital as well as for 
those who are clinically well who could be treated in primary 
care settings.74
How do we initiate and retain children on antiretroviral 
therapy from the neonatal period onwards?
There are substantial challenges with initiating and retaining 
HIV-infected newborns on treatment. The mothers of HIV-
infected infants will frequently have either never accessed 
PMTCT or been lost to care;75,76,77 consequently, the likelihood 
of poor infant retention and adherence after ART initiation 
is high. Studies from both wealthy countries78 and resource-
limited settings79 report substantial loss to follow-up and poor 
adherence on ART in infected infants, despite high coverage 
of an effective PMTCT programme. In a Johannesburg 
research cohort of 30 infants initiating ART at a median 16 
weeks of age, < 50% were in care 68 weeks later, with four 
deaths.79 The challenges that the caregivers of these infants 
may already face with accessing and remaining in care may 
be exacerbated by the tremendous stress experienced with 
EID.80,81,82,83 Significant research gaps include understanding 
the tensions between maternal needs in the post-partum 
period, including the psychosocial readiness of the mother 
to initiate ART for her infant, and how neonatal ART services 
are delivered. Research is needed to investigate approaches 
to EID and neonatal ART initiation, such as the use of heath 
navigators, that best support engagement and long-term 
retention in care.
Future directions
As practice changes towards birth diagnosis and early infant 
ART, there is an opportunity to collect both programme-level 
and individual patient data to address some of the research 
questions related to early neonatal HIV care.84 Just as 
studies of the first paediatric ART programmes in resource-
limited settings were used to inform treatment guidelines 
and programme development,85,86,87 careful collection and 
analysis of observational data from PMTCT, EID and 
neonatal ART programmes will provide valuable evidence 
to inform neonatal HIV care. Collaborative research across 
different sites and settings is needed owing to the small 
numbers of patients at individual sites and transfer of infants 
from PMTCT programmes to neonatal/paediatric and 
primary care ART programmes. Such observational research 
conducted within South Africa and in other resource-limited 
settings will be relevant both locally and globally.84
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